2023
SAT257 Efficacy Of Oral Cinacalcet In Non-PTH Non-Malignant Hypercalcemia From Excess 1,25 Dihydroxyvitamin D
Mohan S, Sheehan M, Tebben P, Wermers R. SAT257 Efficacy Of Oral Cinacalcet In Non-PTH Non-Malignant Hypercalcemia From Excess 1,25 Dihydroxyvitamin D. Journal Of The Endocrine Society 2023, 7: bvad114.553. PMCID: PMC10554413, DOI: 10.1210/jendso/bvad114.553.Peer-Reviewed Original ResearchMale patientsFemale patientsCYP24A1 geneNon-malignantCalcium levelsElevated 1,25-dihydroxyvitamin DNormalization of calcium levelsDecreased intestinal calcium absorptionEstimated glomerular filtration rateFractional excretion of calciumCYP24A1 gene mutationsDiscontinuation of cinacalcetTreated with cinacalcetEnzyme 1-alpha-hydroxylaseYear of therapySerum calcium levelsHypercalcemia of malignancyIntestinal calcium absorptionMaintenance of normocalcemiaGlomerular filtration rateExcretion of calciumSerum calcium concentrationChronic kidney diseasePTH-related peptideOral cinacalcet
2014
Denosumab for Treatment of Hypercalcemia of Malignancy
Hu MI, Glezerman IG, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Ying W, Braun A, Jain RK. Denosumab for Treatment of Hypercalcemia of Malignancy. The Journal Of Clinical Endocrinology & Metabolism 2014, 99: 3144-3152. PMID: 24915117, PMCID: PMC4154084, DOI: 10.1210/jc.2014-1001.Peer-Reviewed Original ResearchConceptsHypercalcemia of malignancyProportion of patientsDay 10Serum calciumBone resorptionCommon serious adverse eventsMedian response durationSerious adverse eventsSerum calcium levelsTreatment of hypercalcemiaDuration of responseNew treatment optionsBisphosphonate therapyPrimary endpointSecondary endpointsAdverse eventsBisphosphonate treatmentDurable responsesComplete responseAdvanced cancerTreatment optionsHematologic malignanciesResponse durationDenosumabCalcium levels
2013
Denosumab For The Treatment Of Hypercalcemia Of Malignancy Refractory To IV Bisphosphonates In Patients With Hematologic Malignancies
Gucalp R, Insogna K, Hu M, Glezerman I, Leboulleux S, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Ying W, Braun A, Jain R. Denosumab For The Treatment Of Hypercalcemia Of Malignancy Refractory To IV Bisphosphonates In Patients With Hematologic Malignancies. Blood 2013, 122: 2536. DOI: 10.1182/blood.v122.21.2536.2536.Peer-Reviewed Original ResearchHypercalcemia of malignancyProportion of patientsSerious adverse eventsTreatment of hypercalcemiaHematologic malignanciesTreatment responseComplete responseDay 10Bisphosphonate treatmentStudy visitRANK ligandAmgen Inc.Unexpected safety findingsKey secondary endpointOpen-label studyHematologic malignancy patientsOverall study populationUse of denosumabKey baseline characteristicsStudy of patientsOff-label useHuman monoclonal antibodyBisphosphonate therapyDenosumab initiationSubcutaneous denosumabDenosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment
Hu MI, Glezerman I, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Ying W, Jain RK. Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment. Journal Of The National Cancer Institute 2013, 105: 1417-1420. PMID: 23990665, PMCID: PMC3776443, DOI: 10.1093/jnci/djt225.Peer-Reviewed Original ResearchConceptsHypercalcemia of malignancyBisphosphonate treatmentResponse durationDay 10Albumin-corrected serum calciumTumor-induced bone resorptionIntravenous bisphosphonate treatmentPrespecified interim analysisMedian response durationProportion of patientsKaplan-Meier methodNew treatment optionsDenosumab initiationIntravenous bisphosphonatesSubcutaneous denosumabPrimary endpointRenal failureComplete responseSerum calciumTreatment optionsHCM patientsBone resorptionDenosumabInterim analysisPatients
2011
Denosumab for Treatment of Hypercalcemia of Malignancy in Patients with Solid Tumors or Hematological Malignancies Refractory to IV Bisphosphonates: A Single-Arm Multicenter Study
Hu M, Gucalp R, Insogna K, Glezerman I, Leboulleux S, Misiorowski W, Yu B, Ying W, Yeh H. Denosumab for Treatment of Hypercalcemia of Malignancy in Patients with Solid Tumors or Hematological Malignancies Refractory to IV Bisphosphonates: A Single-Arm Multicenter Study. Blood 2011, 118: 2483. DOI: 10.1182/blood.v118.21.2483.2483.Peer-Reviewed Original ResearchHypercalcemia of malignancyDose of denosumabTreatment of hypercalcemiaAdverse eventsBP treatmentInterim analysisDay 10RANK ligandComplete responseAdvanced cancerCSC levelsBone resorptionHematological malignanciesTreatment of HCMSolid tumorsSingle-arm multicenter studyAmgen Inc.Denosumab-treated patientsDoses of denosumabStudy day 10Serious adverse eventsSerum calcium levelsSingle-arm studyStudy days 1Population of patientsA single-arm multicenter proof-of-concept study of denosumab to treat hypercalcemia of malignancy in patients who are refractory to IV bisphosphonates.
Hu M, Gucalp R, Insogna K, Glezerman I, Bone H, Jaccard A, Misiorowski W, Yu B, Yeh H. A single-arm multicenter proof-of-concept study of denosumab to treat hypercalcemia of malignancy in patients who are refractory to IV bisphosphonates. Journal Of Clinical Oncology 2011, 29: tps245-tps245. DOI: 10.1200/jco.2011.29.15_suppl.tps245.Peer-Reviewed Original ResearchHypercalcemia of malignancyMulticenter proofConcept studyDenosumabHypercalcemiaPatientsBisphosphonatesMalignancy
2005
Hypercalcemia of Malignancy due to Ectopic Transactivation of the Parathyroid Hormone Gene
VanHouten JN, Yu N, Rimm D, Dotto J, Arnold A, Wysolmerski JJ, Udelsman R. Hypercalcemia of Malignancy due to Ectopic Transactivation of the Parathyroid Hormone Gene. The Journal Of Clinical Endocrinology & Metabolism 2005, 91: 580-583. PMID: 16263810, DOI: 10.1210/jc.2005-2095.Peer-Reviewed Original ResearchMeSH KeywordsAgedDNA MethylationDNA, NeoplasmFatal OutcomeFemaleGene ExpressionHumansHypercalcemiaHyperparathyroidismNeuroendocrine TumorsPancreatic NeoplasmsParathyroid GlandsParathyroid Hormone-Related ProteinPromoter Regions, GeneticReverse Transcriptase Polymerase Chain ReactionTranscriptional Activation
1996
Parathyroid Hormone-Related Protein: From Hypercalcemia of Malignancy to Developmental Regulatory Molecule
Dunbar M, Wysolmerski J, Broadus A. Parathyroid Hormone-Related Protein: From Hypercalcemia of Malignancy to Developmental Regulatory Molecule. The American Journal Of The Medical Sciences 1996, 312: 287-294. DOI: 10.1016/s0002-9629(15)41844-0.Peer-Reviewed Original ResearchConceptsDevelopmental regulatory moleculeCommon metabolic complicationHypercalcemia of malignancyHormone-related proteinParathyroid hormone receptorTypes of cancerMetabolic complicationsHumoral hypercalcemiaParathyroid hormoneRegulatory moleculesParacrine fashionBiochemical manifestationsMalignant cellsHypercalcemiaFetal tissuesPTHrPHormone receptorsNormal biological functionsMalignancyMolecular evolutionHHMBiological functionsMolecular mechanismsComplicationsKidneyParathyroid Hormone-Related Protein: From Hypercalcemia of Malignancy to Developmental Regulatory Molecule
Dunbar M, Wysolmerski J, Broadus A. Parathyroid Hormone-Related Protein: From Hypercalcemia of Malignancy to Developmental Regulatory Molecule. The American Journal Of The Medical Sciences 1996, 312: 287-294. PMID: 8969618, DOI: 10.1097/00000441-199612000-00007.Peer-Reviewed Original ResearchConceptsDevelopmental regulatory moleculeCommon metabolic complicationHypercalcemia of malignancyHormone-related proteinParathyroid hormone receptorTypes of cancerMetabolic complicationsHumoral hypercalcemiaParathyroid hormoneRegulatory moleculesParacrine fashionBiochemical manifestationsMalignant cellsHypercalcemiaFetal tissuesPTHrPHormone receptorsNormal biological functionsMalignancyMolecular evolutionHHMBiological functionsMolecular mechanismsComplicationsKidney
1987
Hypercalcemia of Malignancy
Insogna KL, Broadus AE. Hypercalcemia of Malignancy. Annual Review Of Medicine 1987, 38: 241-256. PMID: 3555293, DOI: 10.1146/annurev.me.38.020187.001325.Books
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply